David Faleck
@davidfaleckmd
Gastroenterologist @sloan_kettering. Focused on IBD, dysplasia, cancer, checkpoint inhibitors, immune-related toxicities
ID: 1003609703849525248
https://www.mskcc.org/cancer-care/doctors/david-faleck 04-06-2018 12:09:34
195 Tweet
396 Takipçi
253 Takip Edilen
Nayantara Coelho #MondayNightIBD Aline Charabaty, MD, FACG, AGAF AbbVie JanssenUS Takeda Nisha Loganantharaj David Fudman, MD Jordan Axelrad, MD, MPH Tanvi Dhere,MD David M. Schwartzberg, MD Stefan Holubar MD MS Edward Loftus Jami Kinnucan, MD, FACG, AGAF, FCCF Pär Myrelid Adam Faye MD MS Memorial Sloan Kettering Cancer Center Agree, no ideal options here. L-sided/rectal neoplasia does pose additional challenges, but if the rectum is quiescent for years on medical therapy and patient understands the limitations (including need for close surveillance of the indef dysplasia) then it can be considered.